Skip to Content

Initiate treatment earlier.

The leading cause of pulmonary renal syndrome.

Pulmonary renal syndrome (PRS) is characterized by rapidly progressive glomerulonephritis (RPGN) and diffuse alveolar hemorrhage secondary to an autoimmune response. The most common causes of PRS in adults are ANCA-associated vasculitis (AAV) and anti-GBM disease. Due to the overlap in clinical presentation, frequency of RPGN, and the need for early diagnosis and treatment, testing for ANCA and anti-GBM is recommended during the differential diagnosis.

Improve outcomes through comprehensive testing.

Prompt identification of ANCA and anti-GBM antibodies allows for early initiation of treatment and may improve patient outcomes. Antibodies to GBM antigens cause glomerulonephritis, Goodpasture’s syndrome, and, less commonly, pulmonary hemosiderosis. Anti-neutrophil cytoplasmic antibodies occur in various types of autoimmune diseases including renal limited vasculitis (e.g., Wegener’s granulomatosis [WG] or microscopic polyangiitis [MPA]) and pauci-immune necrotizing GN.1 Comprehensive testing, prompt result reporting, and access to more than 150 years of advanced medical knowledge deliver the answers your practice needs to keep care local.


Update on the management of ANCA-associated vasculitis

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises three different syndromes — granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis); microscopic polyangiitis (MPA); and eosinophilic granulomatosis with polyangiitis (EGPA, also known as Churg-Strauss syndrome) — all with frequent respiratory manifestations.

Establish the diagnosis

GBM | Glomerular Basement Membrane Antibodies, IgG, Serum

Identifies GBM antibodies to aid in diagnosing anti-GBM disease or Goodpasture’s syndrome.

When to order testing?

  • Evaluate patients with rapid-onset renal failure and evidence of possible anti-GBM disease.
  • Evaluate patients with suspected nephritic syndrome and active urinary sediments to determine the clinical presentation.
  • Evaluate patients with pulmonary hemorrhage.
  • Guide treatment plan development.
  • Monitor treatment effectiveness and progression of renal injury in patients with anti-GBM diseases.
  • In conjunction with the Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum (Mayo ID: VASC) to confirm diagnosis.

Confirm disease subtype

VASC | Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum

Distinguish Wegener’s granulomatosis from microscopic polyangiitis by identifying the presence of antineutrophil cytoplasmic antibodies.

When to order testing?

  • Confirm disease subtype when a patient presents with nephritic syndrome.
  • Establish if a patient with anti-GBM disease is also ANCA positive to predict outcomes.
  • Guide treatment plan development.
  • Confirm initial diagnosis in conjunction with Glomerular Basement Membrane Antibodies, IgG, Serum (Mayo ID: GBM).

Learn more about how to order these evaluations at your institution.